Subject 1008 was enrolled with mCRPC after docetaxel chemotherapy, metastatic to lungs, LNs, and bone, with a Halabi-predicted survival of 12.5 months. He was treated with 6 doses of BPX-101 starting 6 weeks after baseline scans. Six measurable metastatic lesion in the lungs were eliminated by the end of the 12 week induction phase of treatment (20 weeks after baseline scans) (top). Metastases at other sites were stable at 12 weeks. He remains alive with progressive disease 10 months after enrollment. This subject exhibited the highest average fold change in serum cytokine spikes one week following the administration of BPX-101 and AP1903 (bottom, including IL-6 ELISA). The pattern is similar to the late maintenance phase pattern for subject 1003.
We report immunological results from a Phase I/II, non-randomized, multiple-dose, 3+3 dose-escalation study of the safety, pharmacokinetics, biomarkers, preliminary efficacy and patient-reported outcomes of therapeutic vaccine, BPX-101, plus activating agent, AP1903, in patients with mCRPC. A total of 3 cohorts, consisting of 3 to 6 patients each, received every other weekly administration of BPX-101. BPX-101 is comprised of matured, antigen-expressing DCs derived from monocytes collected during an out-patient leukapheresis procedure. By the end of a six day process conducted in a central GMP processing facility, these cells have been transduced with an adenovector encoding iCD40, incubated with a recombinant form of PSMA, and pre-activated with AP1903 and LPS. The resulting vaccine cells are washed and cryopreserved in individual doses (sufficient for about one year of treatment). Each dosing event consists of BPX-101 vaccine administration via multiple intradermal injections. At 24 hours after each vaccination, a single dose of the activating agent, AP1903 for Injection, is administered at a fixed dose of 0.4 mg/kg via intravenous (IV) infusion over 2 hours.
In Cohort 1 and Cohort 2, 1 mL of BPX-101 was administered at each treatment visit as 5 intradermal (ID) injections (200 µL each). In Cohort 3, 1.6 mL of BPX-101 was administered at each treatment visit as 8 intradermal injections (200 µL each). The dose levels for each cohort were as follows: BPX-101 is a therapeutic DC vaccine for the treatment of men with mCRPC. This product pairs DeCIDe™ vaccine technology with a form of the prostate cancer antigen PSMA, in an autologous format. DeCIDe™ technology is an application of Chemical Induction of Dimerization (CID), a cell-signaling technology that enables the regulation of specific cell signaling, gene transcription and protein secretion events in cells and whole organisms, including humans. This is accomplished by administering AP1903, a lipid-permeable "dimerizer" drug, to cells that have been genetically modified to express a chimeric protein containing one or more signaling molecules of interest adjacent to tandem AP1903 drug binding sites. AP1903 crosslinks the binding sites, causing multimerization of the signaling molecules with ensuing initiation of downstream signaling events.
DeCIDe™ vaccines are genetically modified to express an AP1903-activated chimeric version of the DC costimulatory molecule CD40, permitting temporally controlled, lymphoid-localized, DC-specific activation. By eliminating the extracellular domain, iCD40 circumvents mechanisms of negative feedback, leading to a potent and durable antigenspecific T cell immune response, capable of eradicating tumor cells. Preclinical development work conducted at Baylor College of Medicine and published in Nature Medicine (11, 130) and Cancer Research (67, 10528) demonstrates potent in vivo antitumor efficacy with undetected toxicity or autoimmunity.
Serum Cytokine Spikes Relationship to Soft Tissue Clinical Response
The following trends were observed in the 12 patients treated thus far with BPX-101 and AP1903:  A pattern of serum cytokine spiking, one week after each dose, and returning to baseline the following week, was observed in subjects with greatest disease burden.  One low dose subject, who experienced a soft tissue PR after one year on study, showed cytokine spikes averaging 4-fold following each induction phase vaccine dose, which increased to between 6-fold and 56-fold after the final three boosters, with a different pattern.  For this same low dose subject, IL-6, which had declined during the induction phase to below 1 pg/mL through two boosters, spiked between 1,680-fold and 13,000-fold after each of the last three boosters.  One high doses subject who experienced a near CR of multiple lung metastases with otherwise stable disease showed cytokine spikes averaging 150-fold during the induction phase with some spiking greater than 1,000-fold.  Cytokine spikes were not associated with AE's.
 There is a correlative trend between clinical responses (objective disease and PSA) and significant spiking of serum cytokines following vaccination suggesting these cytokine changes may be indicative of anti-tumor immune responses.
Conclusions
Subject 1003 was enrolled with Gleason 9 mCRPC, having failed prior docetaxel chemotherapy with a rising PSA of 312 ng/mL and debilitating back pain. Baseline scans showed retroperitoneal lymphadenopathy, with 8 measurable LNs. PSA fell 46% within 8 weeks of initiating therapy and remained stable through 30 weeks before beginning a consistent rise above baseline again. This patient achieved a soft tissue PR by one year (top). Average fold change in serum cytokine spikes one week following the administration of BPX-101 and AP1903 show an increase in the magnitude and a shift in the pattern of cytokine changes at the third chronic phase booster (bottom, including IL-6 ELISA). This latter pattern is similar to subject 1008 and other high dose subjects.
Relationship to Tumor Burden
Unweighted mean change in cytokine level after each dose, for all cytokines and all six doses, are plotted against baseline PSA, a putative surrogate for tumor burden. In general, patients in the high dose (orange triangle) exhibited the highest magnitude of spiking, and an apparent correlation with tumor burden in the low (blue diamond) and mid dose (green circle) cohorts was less apparent at the high dose.
The pattern of cytokine spiking was somewhat consistent, as illustrated by a qualitative heat map.
Methods: Blood was collected immediately prior to and one week after each vaccination. Centrifuged (1500 g) serum samples were aliquoted and stored in liquid nitrogen for later batch testing. Undiluted samples were analyzed in duplicate using the Milliplex Human Cytokine/Chemokine Panel kit (Millipore, Inc), which includes analytes for GM-CSF, IFN-γ, IL-10, IL-12 (p70), IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IP-10 (CXCL10), MCP-1, MIP-1α, MIP-1β, RANTES, and TNF-α. Data was analyzed using Bio-Plex software (Bio-Rad Laboratories, Inc). IL-6 was measured by ELISA assay.
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